<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017171</url>
  </required_header>
  <id_info>
    <org_study_id>DK101108</org_study_id>
    <secondary_id>UC4DK101108-01</secondary_id>
    <nct_id>NCT02017171</nct_id>
    <nct_alias>NCT01575379</nct_alias>
  </id_info>
  <brief_title>A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes</brief_title>
  <official_title>PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alessandro Doria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BCDiabetes.Ca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite improvements during the past 20 years in blood glucose and blood pressure control,&#xD;
      diabetic kidney disease remains one of the most important causes of health problems in&#xD;
      patients with diabetes. Novel treatments to complement blood glucose and blood pressure&#xD;
      control are urgently needed. The goal of this study is to see whether a medication called&#xD;
      allopurinol may help prevent loss of kidney function among people with type 1 diabetes.&#xD;
      Allopurinol has been used for many years to decrease high blood uric acid and treat gout - a&#xD;
      disease characterized by arthritis, especially of the foot joints. There is evidence&#xD;
      suggesting that allopurinol might also be useful in people with diabetes who have normal or&#xD;
      moderately impaired kidney function to decrease the risk of developing advanced kidney&#xD;
      disease in the future. To prove this beneficial effect of allopurinol, we will be conducting&#xD;
      an international clinical trial at eight diabetes centers, enrolling approximately 480&#xD;
      patients with type 1 diabetes who are at increased risk of developing kidney disease.&#xD;
      Participants will be randomly assigned to take allopurinol or placebo (inactive pill) for&#xD;
      three years, during which they will be followed through periodical visits. To prevent any&#xD;
      possible bias, neither the participants nor the clinical staff knows who is taking&#xD;
      allopurinol and who is taking the placebo. Kidney function will be measured at the beginning&#xD;
      and at the end of the treatment period to see whether patients taking allopurinol experience&#xD;
      a slower loss of kidney function over time as compared to those taking the inactive pill. If&#xD;
      this trial is successful, the reduction in health problems resulting from the prevention or&#xD;
      delay of kidney function loss due to the use of allopurinol would have a major impact on the&#xD;
      lives of type 1 diabetic patients as well as on society at large, significantly reducing the&#xD;
      human and financial costs associated with diabetic kidney disease. Because of the emphasis on&#xD;
      early intervention, the proposed trial, if successful, will establish a new paradigm in&#xD;
      treatments to slow or prevent progression towards end stage kidney disease in type 1 diabetes&#xD;
      far beyond anything achieved to date.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements in the past 20 years in glycemic and blood pressure control and the&#xD;
      introduction of 'renoprotective' drugs such as renin-angiotensin system blockers, the&#xD;
      incidence of end-stage renal disease (ESRD) in type 1 diabetes (T1D) is not declining. Novel&#xD;
      therapies to complement these interventions are urgently needed. Mounting evidence from&#xD;
      prospective studies indicates that moderately elevated serum uric acid is a strong,&#xD;
      independent predictor of an increased risk of chronic kidney disease and increased rates of&#xD;
      loss of kidney function among T1D persons. To study whether uric acid lowering can reduce&#xD;
      glomerular filtration rate (GFR) loss in T1D, we have established the PERL (Preventing Early&#xD;
      Renal Function Loss in Diabetes) Consortium including investigators from Joslin Diabetes&#xD;
      Center, the Universities of Minnesota, Colorado, Toronto, and Michigan, Northwestern&#xD;
      University, Albert Einstein College of Medicine, and the Steno Diabetes Center in Denmark.&#xD;
      With the support of NIH grant R03 DK094484, the Consortium has designed a three-year,&#xD;
      multi-center, double-blind, placebo-controlled, randomized clinical trial with the specific&#xD;
      aim of evaluating the efficacy of the urate-lowering drug allopurinol, as compared to&#xD;
      placebo, in reducing kidney function loss among subjects with T1D. The trial is targeted to&#xD;
      T1D patients with microalbuminuria or moderate macroalbuminuria or ongoing kidney function&#xD;
      decline and serum uric acid levels â‰¥ 4.5 mg/dl, since these are the patients who are at very&#xD;
      high risk of having rapid GFR decline and might benefit most from reductions in uric acid&#xD;
      levels. Study subjects will be required to have a GFR between 40 and 99 ml/min/1.73 m2,&#xD;
      consistent with the goal of intervening relatively early in the course of clinical DN rather&#xD;
      than at later stages when structural changes are far advanced and a very large proportion of&#xD;
      kidney function has already been lost. The primary endpoint of the study will be the GFR (as&#xD;
      measured by iohexol plasma disappearance) at the end of a 2-month wash-out period after the&#xD;
      3-year intervention. Sample size calculations under various dropout and non-adherence&#xD;
      scenarios suggest that 240 subjects in each treatment arm would provide at least 80% power to&#xD;
      detect a clinically meaningful and achievable reduction in GFR decline in the allopurinol vs.&#xD;
      the placebo group.If we demonstrate that allopurinol can halt or slow down GFR decline in T1D&#xD;
      subjects, we will provide a safe and inexpensive intervention to prevent or delay kidney&#xD;
      failure in T1D that can be applied at the earliest clinically detectable stages of renal&#xD;
      injury. It is difficult to overstate how significant this finding would be, both from the&#xD;
      perspective of public health and that of persons with diabetes.&#xD;
&#xD;
      Thirty-one of the 530 participants in this study were recruited as part of a pilot study&#xD;
      (JDRF 17-2012-377, NCT01575379) and transferred to the main study (NCT02017171) when this was&#xD;
      funded. Eligibility criteria for the pilot study were the same as those for the main study,&#xD;
      with the exception of a wider estimated GFR interval at entry in the run-in period&#xD;
      (eGFR=35-109) ml/min/1.73 m2) and the additional requirement of a measured GFR (iGFR) between&#xD;
      45 and 99 ml/min/1.73 m2 at the end of the run-in period. Pilot subjects joined the main&#xD;
      study at a time point corresponding to the time elapsed from randomization in the pilot.&#xD;
      Thus, they were exposed to the study medication for the same length of time (3 years) as&#xD;
      participants who were directly enrolled in the main study. Outcomes measures were those of&#xD;
      the main study, regardless of whether participants were transferred from the pilot or were&#xD;
      directly enrolled in the main study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iGFR at the End of the Wash-out Period</measure>
    <time_frame>End of the 2-month wash-out period following the 3-year treatment period (week 164)</time_frame>
    <description>Glomerular filtration rate (GFR) at the end of the 2-month wash-out period following the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eGFR at 4 Months of Treatment</measure>
    <time_frame>4 months after randomization (week 16)</time_frame>
    <description>Glomerular filtration rate (GFR) at 4 months after randomization, estimated from serum creatinine and cystatin C and adjusted for the eGFR at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iGFR the End of Treatment Period</measure>
    <time_frame>End of the 3-yr treatment period (week 156)</time_frame>
    <description>Glomerular filtration rate (GFR) at the end of the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iGFR Time Trajectory</measure>
    <time_frame>Weeks 0, 80, 156, and 164 (from baseline to the end of washout period)</time_frame>
    <description>Glomerular filtration rate time trajectory estimated from iohexol disappearance GFR (iGFR) measurements at weeks 0, 80, 156, and 164. iGFR slopes were estimated by a linear mixed-effects model for longitudinal iGFR measures using a multiple imputation technique for missing values. Positive values denote increasing GFR over time, negative values denote declining iGFR over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR Time Trajectory</measure>
    <time_frame>Weeks 0, 4, 16, 32, 48, 64, 80, 96, 112, 128, 156, and 164 (from baseline to the end of washout period)</time_frame>
    <description>Glomerular filtration rate time trajectory from baseline to end of the 2-month wash-out period (week 164) estimated from quarterly serum creatinine measurements (eGFR). eGFR slopes were estimated by a linear mixed-effects model for longitudinal eGFR measures using a multiple imputation technique for missing values. Positive values denote increasing eGFR over time, negative values denote declining eGFR over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine Doubling or End Stage Renal Disease (ESRD)</measure>
    <time_frame>Up to the end of the 2-month wash-out period following the 3-year treatment period (Week 0 to Week 164)</time_frame>
    <description>Risk of serum creatinine doubling or end stage renal disease (ESRD) in the allopurinol arm as compared to placebo. Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AER at the End of the Wash-out Period</measure>
    <time_frame>End of the 2-month wash-out period following the 3-year treatment period (week 164)</time_frame>
    <description>Geometric mean of two urinary albumin excretion (AER) measurements at the end of the 2-month wash-out period following the 3-year treatment period, adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AER at the End of the Treatment Period</measure>
    <time_frame>Last three months of treatment period (Weeks 142 and 156)</time_frame>
    <description>Geometric mean of urinary albumin excretion rate (AER) during the last three months of the treatment period (Visits 15 and 16), adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal or Non-fatal Cardiovascular Events</measure>
    <time_frame>Up to the end of the 2-month wash-out period following the 3-year treatment period (week 0 to 164)</time_frame>
    <description>Risk of cardiovascular events defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke (ischemic or hemorrhagic), coronary artery bypass grafting, or percutaneous coronary intervention in the allopurinol arm as compared to placebo.Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive oral tablets identical in appearance to allopurinol tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with type 1 diabetes continuously treated with insulin within&#xD;
             one year from diagnosis&#xD;
&#xD;
          -  Duration of T1D â‰¥ 8 years&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  History or presence of microalbuminuria or moderate macroalbuminuria, or evidence of&#xD;
             declining kidney function regardless of history or presence of albuminuria and/or RAS&#xD;
             Blocker treatment. Micro- or moderate macroalbuminuria will be defined as at least two&#xD;
             out of three consecutive urinary albumin excretion rates [AERs] or albumin creatinine&#xD;
             ratios [ACRs] taken at any time during the two years before screening or at screening&#xD;
             in the 30-5000 mg/24 hr (20-3333 ug/min) or 30-5000 mg/g range, respectively, if not&#xD;
             on RASB agents, or in the 18-5000 mg/24 hr (12-3333 ug/min) or 18-5000 mg/g range,&#xD;
             respectively, if on RASB agents). Evidence of declining kidney function will be&#xD;
             defined as an eGFR (CKD-EPI) decline â‰¥3.0 ml/min/1.73 m2/year, estimated from the&#xD;
             slope derived from all the available serum creatinine measurements (including the one&#xD;
             at screening assessment) from the previous 3 years. If at least 3 serum creatinine&#xD;
             measures are not available in the previous 3 years, then the slope can be derived from&#xD;
             creatinine values from the previous 5 years.&#xD;
&#xD;
          -  Estimated GFR (eGFR) based on serum creatinine between 40 and 99.9 ml/min/1.73 m2 at&#xD;
             screening. The upper and the lower limits should be decreased by 1 ml/min/1.73 m2 for&#xD;
             each year over age 60 (with a lower limit of 35 ml/min/1.73m2) and by 10 ml/min/1.73&#xD;
             m2 for strict vegans.&#xD;
&#xD;
          -  Serum UA (UA) â‰¥ 4.5 mg/dl at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of gout or xanthinuria or other indications for uric acid lowering therapy&#xD;
             such as cancer chemotherapy.&#xD;
&#xD;
          -  Recurrent renal calculi.&#xD;
&#xD;
          -  Use of urate-lowering agents within 2 months before screening.&#xD;
&#xD;
          -  Current use of azathioprine, 6-mercaptopurine, didanosine, warfarin, tamoxifen,&#xD;
             amoxicillin/ampicillin, or other drugs interacting with allopurinol.&#xD;
&#xD;
          -  Known allergy to xanthine-oxidase inhibitors or iodine containing substances.&#xD;
&#xD;
          -  HLA B*58:01 positivity (tested before randomization).&#xD;
&#xD;
          -  Renal transplant.&#xD;
&#xD;
          -  Non-diabetic kidney disease.&#xD;
&#xD;
          -  SBP&gt;160 or DBP &gt;100 mmHg at screening or SBP&gt;150 or DBP&gt;95 mmHg at the end of the&#xD;
             run-in period.&#xD;
&#xD;
          -  Cancer treatment (excluding non-melanoma skin cancer treated by excision) within two&#xD;
             years before screening.&#xD;
&#xD;
          -  History of clinically significant hepatic disease including hepatitis B or C and/or&#xD;
             persistently elevated serum liver enzymes at screening and/or history of HBV/HCV&#xD;
             positivity.&#xD;
&#xD;
          -  History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)&#xD;
             infection.&#xD;
&#xD;
          -  Hemoglobin concentration &lt;11 g/dL (males), &lt;10 g/dL (females) at screening.&#xD;
&#xD;
          -  Platelet count &lt;100,000/mm3 at screening.&#xD;
&#xD;
          -  History of alcohol or drug abuse in the past 6 months.&#xD;
&#xD;
          -  Blood donation in the 3 months before screening.&#xD;
&#xD;
          -  Breastfeeding or pregnancy or unwillingness to be on contraception throughout the&#xD;
             trial.&#xD;
&#xD;
          -  Poor mental function or any other reason to expect patient difficulty in complying&#xD;
             with the requirements of the study.&#xD;
&#xD;
          -  Serious pre-existing medical problems other than diabetes, e.g. congestive heart&#xD;
             failure, pulmonary insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Doria, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Mauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Davis Center / University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Colorado Institute of Health Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University - Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Health Care</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brehm Center for Diabetes Research / University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine / Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop-University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICAHN School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunderson Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Diabetes Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Diabetes</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Y 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes and Endocrinology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital / University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://perl-study.org/</url>
    <description>Study website</description>
  </link>
  <reference>
    <citation>Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, Weinberg JM, Aschengrau A, Eckfeldt JH, Stanton RC, Galecki AT, Doria A, Warram JH, Krolewski AS. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care. 2010 Jun;33(6):1337-43. doi: 10.2337/dc10-0227. Epub 2010 Mar 23.</citation>
    <PMID>20332356</PMID>
  </reference>
  <reference>
    <citation>Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes. 2009 Jul;58(7):1668-71. doi: 10.2337/db09-0014. Epub 2009 May 1. Erratum in: Diabetes. 2010 Oct;59(10):2695.</citation>
    <PMID>19411615</PMID>
  </reference>
  <reference>
    <citation>Jalal DI, Rivard CJ, Johnson RJ, Maahs DM, McFann K, Rewers M, Snell-Bergeon JK. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant. 2010 Jun;25(6):1865-9. doi: 10.1093/ndt/gfp740. Epub 2010 Jan 11.</citation>
    <PMID>20064950</PMID>
  </reference>
  <reference>
    <citation>Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A; PERL Consortium. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013 Aug;13(4):550-9. doi: 10.1007/s11892-013-0381-0. Review.</citation>
    <PMID>23649945</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <results_first_submitted>October 7, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Joslin Diabetes Center</investigator_affiliation>
    <investigator_full_name>Alessandro Doria</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Diabetic Nephropathies</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Complications</keyword>
  <keyword>Uric acid</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02017171/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02017171/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allopurinol</title>
          <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ESKD</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allopurinol</title>
          <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="263"/>
            <count group_id="B3" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" spread="11.2"/>
                    <measurement group_id="B2" value="51.8" spread="10.6"/>
                    <measurement group_id="B3" value="51.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="504"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>BMI values were missing for two participants in the allopurinol group and three participants in the placebo group.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="265"/>
                    <count group_id="B2" value="260"/>
                    <count group_id="B3" value="525"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="6.1"/>
                    <measurement group_id="B2" value="29.5" spread="5.9"/>
                    <measurement group_id="B3" value="29.5" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin (HbA1c)</title>
          <population>HbA1c values were missing for two participants in the Allopurinol group</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="265"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="528"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.3"/>
                    <measurement group_id="B2" value="8.2" spread="1.3"/>
                    <measurement group_id="B3" value="8.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum uric acid</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="1.5"/>
                    <measurement group_id="B2" value="6.1" spread="1.5"/>
                    <measurement group_id="B3" value="6.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <description>Glomerular filtration rate estimated from serum creatinine with the CKD-EPI equation</description>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.4" spread="18.7"/>
                    <measurement group_id="B2" value="74.0" spread="19.4"/>
                    <measurement group_id="B3" value="74.7" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Measured (iohexol-based) glomerular filtration rate (iGFR)</title>
          <description>Glomerular filtration rate measured by the plasma disappearance of an i.v. bolus of the contrast medium iohexol</description>
          <population>Measured GFR value was missing for one participant in the placebo group</population>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="262"/>
                    <count group_id="B3" value="529"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.7" spread="17.1"/>
                    <measurement group_id="B2" value="67.3" spread="16.7"/>
                    <measurement group_id="B3" value="68" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="12.2"/>
                    <measurement group_id="B2" value="35.3" spread="12.5"/>
                    <measurement group_id="B3" value="34.6" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.6" spread="14.7"/>
                    <measurement group_id="B2" value="126.3" spread="13.6"/>
                    <measurement group_id="B3" value="126.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.2" spread="10.4"/>
                    <measurement group_id="B2" value="71.3" spread="10.0"/>
                    <measurement group_id="B3" value="71.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary albumin excretion rate (AER)</title>
          <population>Urinary AER values were missing for two participants in the placebo group.</population>
          <units>ug/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="261"/>
                    <count group_id="B3" value="528"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" lower_limit="7.7" upper_limit="216.0"/>
                    <measurement group_id="B2" value="43.0" lower_limit="9.0" upper_limit="198.0"/>
                    <measurement group_id="B3" value="41.6" lower_limit="8.5" upper_limit="207.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albuminuria</title>
          <description>Based on overnight urinary albumin excretion rate (AER): normoalbuminuria: AER&lt;20 ug/min, microalbuminuria: AER 20-199 ug/min, macroalbuminuria: AER =&gt; 200 ug/min</description>
          <population>Urinary AER values were missing for two participants in the placebo group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="261"/>
                    <count group_id="B3" value="528"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normoalbuminuria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Microalabuminuria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Macroalbuminuria</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of renin-angiotensin inhibitors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="267"/>
                    <count group_id="B2" value="263"/>
                    <count group_id="B3" value="530"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Past</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>iGFR at the End of the Wash-out Period</title>
        <description>Glomerular filtration rate (GFR) at the end of the 2-month wash-out period following the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
        <time_frame>End of the 2-month wash-out period following the 3-year treatment period (week 164)</time_frame>
        <population>Intention-to-treat population with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (inactive oral tablets identical in appearance to allopurinol tablets).</description>
          </group>
        </group_list>
        <measure>
          <title>iGFR at the End of the Wash-out Period</title>
          <description>Glomerular filtration rate (GFR) at the end of the 2-month wash-out period following the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
          <population>Intention-to-treat population with missing values being imputed</population>
          <units>ml/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.2" lower_limit="58.1" upper_limit="64.2"/>
                    <measurement group_id="O2" value="61.2" lower_limit="58.1" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.999</p_value>
            <p_value_desc>p value is not adjusted for multiple comparisons, a priori threshold for statistical significance: p&lt;0.05</p_value_desc>
            <method>linear model for correlated errors</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Treatment difference = Allopurinol-Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR at 4 Months of Treatment</title>
        <description>Glomerular filtration rate (GFR) at 4 months after randomization, estimated from serum creatinine and cystatin C and adjusted for the eGFR at baseline.</description>
        <time_frame>4 months after randomization (week 16)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR at 4 Months of Treatment</title>
          <description>Glomerular filtration rate (GFR) at 4 months after randomization, estimated from serum creatinine and cystatin C and adjusted for the eGFR at baseline.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ml/min/1.73 m2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3" lower_limit="67.3" upper_limit="73.3"/>
                    <measurement group_id="O2" value="70.0" lower_limit="67.1" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Treatment difference = Allopurinol - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>iGFR the End of Treatment Period</title>
        <description>Glomerular filtration rate (GFR) at the end of the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
        <time_frame>End of the 3-yr treatment period (week 156)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>iGFR the End of Treatment Period</title>
          <description>Glomerular filtration rate (GFR) at the end of the 3-year treatment period, measured by the plasma disappearance of non-radioactive iohexol (iGFR) and adjusted for the iGFR at baseline.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ml/min/1.73 m2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" lower_limit="58.3" upper_limit="64.3"/>
                    <measurement group_id="O2" value="61.0" lower_limit="57.9" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Treatment difference = Allopurinol - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>iGFR Time Trajectory</title>
        <description>Glomerular filtration rate time trajectory estimated from iohexol disappearance GFR (iGFR) measurements at weeks 0, 80, 156, and 164. iGFR slopes were estimated by a linear mixed-effects model for longitudinal iGFR measures using a multiple imputation technique for missing values. Positive values denote increasing GFR over time, negative values denote declining iGFR over time.</description>
        <time_frame>Weeks 0, 80, 156, and 164 (from baseline to the end of washout period)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>iGFR Time Trajectory</title>
          <description>Glomerular filtration rate time trajectory estimated from iohexol disappearance GFR (iGFR) measurements at weeks 0, 80, 156, and 164. iGFR slopes were estimated by a linear mixed-effects model for longitudinal iGFR measures using a multiple imputation technique for missing values. Positive values denote increasing GFR over time, negative values denote declining iGFR over time.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ml/min/1.73 m2/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-3.7" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-2.5" lower_limit="-3.1" upper_limit="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Treatment difference = Allopurinol - Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eGFR Time Trajectory</title>
        <description>Glomerular filtration rate time trajectory from baseline to end of the 2-month wash-out period (week 164) estimated from quarterly serum creatinine measurements (eGFR). eGFR slopes were estimated by a linear mixed-effects model for longitudinal eGFR measures using a multiple imputation technique for missing values. Positive values denote increasing eGFR over time, negative values denote declining eGFR over time.</description>
        <time_frame>Weeks 0, 4, 16, 32, 48, 64, 80, 96, 112, 128, 156, and 164 (from baseline to the end of washout period)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>eGFR Time Trajectory</title>
          <description>Glomerular filtration rate time trajectory from baseline to end of the 2-month wash-out period (week 164) estimated from quarterly serum creatinine measurements (eGFR). eGFR slopes were estimated by a linear mixed-effects model for longitudinal eGFR measures using a multiple imputation technique for missing values. Positive values denote increasing eGFR over time, negative values denote declining eGFR over time.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ml/min/1.73 m2/year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-2.9" upper_limit="-1.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-2.6" upper_limit="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Treatment difference = Allopurinol - Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine Doubling or End Stage Renal Disease (ESRD)</title>
        <description>Risk of serum creatinine doubling or end stage renal disease (ESRD) in the allopurinol arm as compared to placebo. Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
        <time_frame>Up to the end of the 2-month wash-out period following the 3-year treatment period (Week 0 to Week 164)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Doubling or End Stage Renal Disease (ESRD)</title>
          <description>Risk of serum creatinine doubling or end stage renal disease (ESRD) in the allopurinol arm as compared to placebo. Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
            <estimate_desc>Hazard ratio = Allopurinol / Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AER at the End of the Wash-out Period</title>
        <description>Geometric mean of two urinary albumin excretion (AER) measurements at the end of the 2-month wash-out period following the 3-year treatment period, adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
        <time_frame>End of the 2-month wash-out period following the 3-year treatment period (week 164)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>AER at the End of the Wash-out Period</title>
          <description>Geometric mean of two urinary albumin excretion (AER) measurements at the end of the 2-month wash-out period following the 3-year treatment period, adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ug/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="24.7" upper_limit="74.4"/>
                    <measurement group_id="O2" value="31.7" lower_limit="19.5" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio (Final Values)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Ratio = Allopurinol / Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AER at the End of the Treatment Period</title>
        <description>Geometric mean of urinary albumin excretion rate (AER) during the last three months of the treatment period (Visits 15 and 16), adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
        <time_frame>Last three months of treatment period (Weeks 142 and 156)</time_frame>
        <population>Intention-to-treat population, with missing values being imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>AER at the End of the Treatment Period</title>
          <description>Geometric mean of urinary albumin excretion rate (AER) during the last three months of the treatment period (Visits 15 and 16), adjusted for the mean urinary AER at baseline. Results are expressed as least square means of the geometric means in each subject in each group.</description>
          <population>Intention-to-treat population, with missing values being imputed</population>
          <units>ug/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="32.5" upper_limit="70.6"/>
                    <measurement group_id="O2" value="37.4" lower_limit="25.3" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Ratio (Final Values)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <other_analysis_desc>Ratio = Allopurinol / Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatal or Non-fatal Cardiovascular Events</title>
        <description>Risk of cardiovascular events defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke (ischemic or hemorrhagic), coronary artery bypass grafting, or percutaneous coronary intervention in the allopurinol arm as compared to placebo.Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
        <time_frame>Up to the end of the 2-month wash-out period following the 3-year treatment period (week 0 to 164)</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Allopurinol</title>
            <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Fatal or Non-fatal Cardiovascular Events</title>
          <description>Risk of cardiovascular events defined as the composite of CVD death (ICD-10 code I10 to I74.9), myocardial infarction, stroke (ischemic or hemorrhagic), coronary artery bypass grafting, or percutaneous coronary intervention in the allopurinol arm as compared to placebo.Results are expressed as the number of participants who experienced an event in each treatment group. The risk of an event in the allopurinol group as compared to the risk in the placebo group is expressed as hazard ratio (estimated by means of proportional hazard regression).</description>
          <population>Intention-to-treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Hazard Ratio = Allopurinol / Placebo. Confidence intervals are not adjusted for multiplicity and should not be used to infer treatment effects.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In each participants, adverse event data were collected from randomization to two months after the end of pharmacological treatment, or until study discontinuation for participants who did not complete the study. This corresponds to up to 164 weeks for participants who completed the study.</time_frame>
      <desc>The definition of Adverse Events and/or Serious Adverse Events correspond to that from the clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Allopurinol</title>
          <description>Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral placebo tablets (Inactive oral tablets identical in appearance to allopurinol tablets)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1 to 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="267"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Brugada syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia of malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diabetic gastropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Oedema due to renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Herpes simplex meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="267"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="267"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Insertion of ambulatory peritoneal catheter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Penile prosthesis insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1 to 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="267"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="267"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="267"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="47" subjects_affected="31" subjects_at_risk="267"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="267"/>
                <counts group_id="E2" events="36" subjects_affected="21" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="267"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="267"/>
                <counts group_id="E2" events="47" subjects_affected="29" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="267"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="58" subjects_affected="43" subjects_at_risk="267"/>
                <counts group_id="E2" events="45" subjects_affected="39" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alessandro Doria (Sponsor and PI of the study)</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-319-0970</phone>
      <email>alessandro.doria@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

